Friedrich-Baur-Institute, Department of Neurology, Ludwig-Maximilians-University Munich, Ziemssenstrasse 1, D-80336 Munich, Germany.
BMC Med Genet. 2013 Sep 16;14:92. doi: 10.1186/1471-2350-14-92.
We report on a patient with genetically confirmed overlapping diagnoses of CMT1A and FSHD. This case adds to the increasing number of unique patients presenting with atypical phenotypes, particularly in FSHD. Even if a mutation in one disease gene has been found, further genetic testing might be warranted in cases with unusual clinical presentation.
The reported 53 years old male patient suffered from walking difficulties and foot deformities first noticed at age 20. Later on, he developed scapuloperoneal and truncal muscle weakness, along with atrophy of the intrinsic hand and foot muscles, pes cavus, claw toes and a distal symmetric hypoesthesia. Motor nerve conduction velocities were reduced to 20 m/s in the upper extremities, and not educible in the lower extremities, sensory nerve conduction velocities were not attainable. Electromyography showed both, myopathic and neurogenic changes. A muscle biopsy taken from the tibialis anterior muscle showed a mild myopathy with some neurogenic findings and hypertrophic type 1 fibers. Whole-body muscle MRI revealed severe changes in the lower leg muscles, tibialis anterior and gastrocnemius muscles were highly replaced by fatty tissue. Additionally, fatty degeneration of shoulder girdle and straight back muscles, and atrophy of dorsal upper leg muscles were seen. Taken together, the presenting features suggested both, a neuropathy and a myopathy. Patient's family history suggested an autosomal dominant inheritance.Molecular testing revealed both, a hereditary motor and sensory neuropathy type 1A (HMSN1A, also called Charcot-Marie-Tooth neuropathy 1A, CMT1A) due to a PMP22 gene duplication and facioscapulohumeral muscular dystrophy (FSHD) due to a partial deletion of the D4Z4 locus (19 kb).
Molecular testing in hereditary neuromuscular disorders has led to the identification of an increasing number of atypical phenotypes. Nevertheless, finding the right diagnosis is crucial for the patient in order to obtain adequate medical care and appropriate genetic counseling, especially in the background of arising curative therapies.
我们报告了一例基因确诊为重叠性 CMT1A 和 FSHD 的患者。该病例增加了具有非典型表型的独特患者数量,尤其是在 FSHD 中。即使已经发现一种疾病基因的突变,对于具有不典型临床表现的病例,进一步的基因检测可能是必要的。
报告的 53 岁男性患者,20 岁时首次出现行走困难和足部畸形,随后出现肩胛带-骨盆带和躯干肌肉无力,同时伴有手部和足部内在肌、高弓足、爪状趾和远端对称性感觉减退的萎缩。上肢运动神经传导速度降低至 20m/s,下肢无法引出,感觉神经传导速度无法达到。肌电图显示既有肌病改变,也有神经源性改变。取自胫骨前肌的肌肉活检显示轻度肌病,伴有一些神经源性表现和肥大 1 型纤维。全身肌肉 MRI 显示小腿肌肉、胫骨前肌和腓肠肌严重改变,高度被脂肪组织取代。此外,还可见肩胛带和直背肌肉的脂肪变性以及背上部腿肌的萎缩。综合来看,这些表现提示既有神经病变,也有肌病。患者的家族史提示常染色体显性遗传。分子检测显示,患者同时患有遗传性运动感觉神经病 1A 型(HMSN1A,也称为夏科-马里-图思病 1A,CMT1A),是由于 PMP22 基因重复引起的,以及面肩肱型肌营养不良症(FSHD),是由于 D4Z4 基因座(19kb)部分缺失引起的。
遗传性神经肌肉疾病的分子检测导致越来越多的不典型表型被识别。然而,对于患者来说,找到正确的诊断至关重要,以便获得适当的医疗护理和适当的遗传咨询,特别是在出现有治愈潜力的治疗方法的背景下。